Advanced Diagnostic Solutions
AccessDx Laboratory provides advanced diagnostic solutions for personalized medicine, infectious disease programs, and COVID-19 testing. AccessDx Laboratory technologies include advanced molecular diagnostics platforms, next generation sequencing capabilities, and high throughput sample processing capabilities. AccessDx Lab has proven its expertise and the scalability of its platforms for thousands of client groups including large national health systems, municipalities, long-term care organizations, employers, pharmacists, and providers.
The AccessDx Pharmacogenomics Profile (PGx)
The AccessDx PGx Profile assesses a targeted range of individual genes and genetic variants – based on the most current, evidence-based clinical information available. Providers can then incorporate results into their overall clinical assessment to personalize treatments for patients, helping them achieve optimal results with fewer side effects.
Hereditary Cancer Testing (CGx)
The AccessDx Hereditary Cancer (CGx) screening assay analyzes causative variants involved in some of the most common hereditary cancers with relatively high population occurrences. This molecular diagnostics program enables clinical providers and patients to make proactive decisions about prevention options, lifestyle choices, and potential therapies.
COVID-19 Diagnostic Solutions
COVID-19 PCR Testing
PCR-based testing remains the gold standard for the identification of current infections in both symptomatic and asymptomatic individuals. AccessDx provides high-quality clinical-grade RT-PCR tests that are compliant with the FDA’s in-effect policy guidance for COVID-19 testing performed by CLIA-certified laboratories.
COVID-19 Flu Combo PCR Testing
The AccessDx COVID-19 + Flu Combo testing is a combined assay, incorporating our gold-standard COVID PCR diagnostic test with an influenza A+B panel, which identifies individual infections or co-infections. This testing is available under the FDA’s emergency use authorization (EUA) outlined for COVID-19 diagnostic testing.
COVID-19 Antibody Testing
The AccessDx COVID-19 Antibody testing is laboratory-based diagnostics designed to identify the presence of IgG antibodies from a patient’s blood sample. This test identifies individuals who have had previous exposure to the SARS-CoV-2 virus, even if they remained asymptomatic. Antibody testing is compliant with the FDA’s in-effect policy guidance for COVID-19 testing performed by CLIA-certified laboratories.
Infectious Disease Diagnostics
Gastrointestinal Pathogen Panel Testing (GI)
The AccessDx Gastrointestinal Pathogen Panel testing quickly identifies several enteropathogenic viruses, bacteria, and parasites responsible for gastroenteritis by utilizing multiplex quantitative Real-time PCR. It precisely detects the pathogens during single or coinfections and identifies antibiotic drug resistance in one single test. It also facilitates antibiotic stewardship by pinpointing situations for which antibiotics should be avoided.
Influenza A+B Testing (Flu)
The AccessDx Influenza (flu) A+B testing quickly identifies the A and B strains of the flu virus. This testing is a high-quality, clinical-grade PCR test, which delivers accurate diagnoses quickly, allowing providers to initiate the best treatments sooner.
Nail Pathogen Panel Testing (NPP)
With the AccessDx Nail Pathogen Panel testing, physicians can identify a fungal toenail infection quickly with the added benefit of species identification. The panel can detect both fungi and bacteria from the microbial nail flora.
Respiratory Pathogen Panel Testing (RPP)
The AccessDx Laboratory Respiratory Pathogen Panel testing rapidly detects and differentiates a wide range of viral and bacterial pathogens so effective treatment can begin sooner.
Urinary Tract Infection Panel Testing
Urinary tract infections (UTIs) are the most common infections requiring medical attention and a leading justification for antibiotic prescription. AccessDx molecular diagnostic testing accurately detects uropathogens and improves treatment selection while preserving antibiotic stewardship. These enhancements in both speed and accuracy compared with traditional detection methods improve the clinical decisioning process, drive lower overall care costs and readmits, improve outcomes, and creating operational efficiencies for the healthcare team.
Wound Pathogen Panel Testing (WPP)
The AccessDx Laboratory Wound Pathogen Panel Testing (WPP) rapidly establishes the microbiological profile of a sample and simultaneously reveals antibiotic resistance genes. This diagnostic uses a molecular-based analysis platform that provides enhanced precision and speed for species identification when compared to conventional cultures.
Advanced Toxicology Screening
Toxicology screens are typically used to identify chemicals, drugs, or toxins that may impact a patient’s health or plan of care. AccessDx Lab’s toxicology screening programs are molecular-based diagnostics that support both traditional urinalysis and simplified oral samples to rapidly identify the presence of target substances. Oral samples are especially useful for patients that are unable to urinate at the time of testing or for facilities that require gender-neutral specimen collection.